Results 61 to 70 of about 8,964 (253)

Paediatric Behçet's disease: a UK tertiary centre experience [PDF]

open access: yes, 2016
There are currently limited data regarding paediatric Behçet's disease (BD), particularly in the UK. We describe the clinical spectrum, treatment and outcome of BD, and explore the relative sensitivities of the criteria for the diagnosis of BD in a UK ...
Ambrose, N   +4 more
core   +1 more source

Integrated Transcriptome and Metabolomics Analyses Show MYC as a Potential Therapeutic Target for Behçet's Uveitis

open access: yesAdvanced Science, Volume 12, Issue 36, September 25, 2025.
Integrated single‐cell transcriptomic and metabolomic analyses reveal that MYC‐driven glycolysis activates the PI3K‐AKT‐FOXO1 pathway, disrupting Th17/Treg balance and promoting uveitis. MYC inhibition restores immune homeostasis and alleviates disease symptoms.
He Li   +11 more
wiley   +1 more source

Management of recurrent inflammatory choroidal neovascular membrane secondary to Vogt-Koyanagi-Harada syndrome, using combined intravitreal injection of bevacizumab and triamcinolone acetate

open access: yesIndian Journal of Ophthalmology, 2012
The purpose of this report is to evaluate the efficacy and safety of combined intravitreal injection of bevacizumab and intravitreal triamcinolone acetonide (IVTA) for recurrent inflammatory choroidal neovascular membrane (CNVM).
Sivakami A Pai   +2 more
doaj   +1 more source

Adalimumab in Patients with Active Noninfectious Uveitis [PDF]

open access: yes, 2016
Background Patients with noninfectious uveitis are at risk for long-term complications of uncontrolled inflammation, as well as for the adverse effects of long-term glucocorticoid therapy.
Barisani-Asenbauer, Talin   +16 more
core   +4 more sources

Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study

open access: yesArthritis &Rheumatology, Volume 77, Issue 9, Page 1254-1262, September 2025.
Objective This study aims to assess the risk of noninfectious uveitis (NIU) relapse in pediatric patients undergoing adalimumab (ADA) tapering, evaluating potential predictors of such risk. Methods We conducted a multicenter retrospective cohort study involving pediatric patients with NIU who underwent ADA tapering due to inactive uveitis.
Achille Marino   +31 more
wiley   +1 more source

Multimodal imaging ocular sarcoidosis

open access: yesThe Pan-American Journal of Ophthalmology, 2019
The study objective was to present multimodal imaging of definite ocular sarcoidosis (OS) in a young adult. A 52-year old woman consulted for 5 days of photophobia, ocular pain on movement, and redness in her left eye.
Jaime Larrea   +3 more
doaj   +1 more source

Primary Intraocular Lymphoma in a Patient with Bilateral Epstein-Barr Virus Panuveitis

open access: yesCase Reports in Ophthalmological Medicine, 2021
Purpose. Herein, we report a case of primary intraocular lymphoma (PIOL) with the first presentation of bilateral Epstein-Barr virus- (EBV-) associated panuveitis. Case Presentation.
Seyedeh Maryam Hosseini   +3 more
doaj   +1 more source

Severe panuveitis in neuro-Behçet’s disease in Malaysia: a case series [PDF]

open access: yes, 2017
Behçet’s disease (BD) is a multisystemic disease that is very rare in Malaysia. About 5% of patients develop central nervous system involvement, termed neuro-Behçet’s.
Ahmad Tajudin, Liza Sharmini   +5 more
core  

Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III [PDF]

open access: yes, 2018
PURPOSE: To evaluate safety and efficacy of adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. DESIGN: Phase 3, open-label, multicenter clinical trial extension (VISUAL III).
Adán, A   +23 more
core   +1 more source

Morphological assessment of the retina in uveitis [PDF]

open access: yes, 2016
BACKGROUND: The objective of this study is to describe a system for color photograph evaluation in uveitis and report baseline morphologic findings for the Multicenter Uveitis Steroid Treatment (MUST) Trial. Four-hundred seventy-nine eyes of 255 subjects
Altaweel, Michael M   +10 more
core   +3 more sources

Home - About - Disclaimer - Privacy